Merck KGaA · XETR:MRK

Merck KGaA — Merck KGaA, Darmstadt, Germany — Morgan Stanley European Technology, Media & Telecom Conference 2021

123 slides from Merck KGaA's conference presentation, November 2021

  1. Slide 1: Morgan Stanley European Technology, Media & Telecom Conference

    MeRck Morgan Stanley - European Technology, Media & Telecom Conference Investor Relations November 2021

  2. Slide 2: Disclaimer

    Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other wor

  3. Slide 3: Agenda

    Agenda 01 Business overview 02 Transforming the company 03 Healthcare – Executing on the earnings phase 04 Life Science – Focusing on profitable growth 05 Electronics – Leveraging portfolio shift 06 Sustainability 07 Guidance & executive summary 3

  4. Slide 4: Business overview

    BuUSsINeSS overview

  5. Slide 5: Leading positions in fastest growing science & technology markets

    Merck Group Leading positions in fastest growing science & technology markets Share of Share of net sales EBITDA pre Strong portfolio & performance drive above-market growth Leading positions and capabilities in core business areas (esp. BioP) 42% 45% New high-growth segments (e.g. novel modalities,

  6. Slide 6: Supporting pillars

    Merck Group Accelerated science & tech leadership driving growth New Strategic Framework Core pillars Direction Mobilize for growth Focus on profitable top line growth in the BIG3 in BIG3 Frame Accelerating science & Innovation as key driver for technology leadership sustainable growth Foundation Fo

  7. Slide 7: 2021 and beyond – poised for growth in a challenging environment

    Merck Group 2021 and beyond – poised for growth in a challenging environment Trade Wars Group-wide: Profitable Growth & Cost Discipline Life Science Healthcare Electronics ▪ Continued strong mid- ▪ Drive profitable growth ▪ Accelerate top-line China Auto term outlook through pipeline growth Sustain

  8. Slide 8: Transforming the company

    Transforming the company

  9. Slide 9: Added scale and strengthened attractiveness of portfolio

    Merck Group Added scale and strengthened attractiveness of portfolio Growth trajectory Transformation volume5 ~€10 bn ~€36 bn Divestments Acquisitions - divested + acquired 1 2 3 Included since 2 May 2014; 2007 and 2014 EBITDA pre margin adjusted for comparability; 2018 net sales reflect Consumer He

  10. Slide 10: Well positioned to win in high-growth focus areas

    Merck Group Well positioned to win in high-growth focus areas Global economy1 End markets1 Focus market areas1 BIG3 Global pharma industry Oncology ~9% to 12% New HC ~4% to 5% Neurology ~3% to 6% Products Global life science industry Biologics >10% Process ~5% to 7% Services >10% Solutions Global el

  11. Slide 11: #25by25: delivering €5 bn+ organic additional sales by 2025

    Merck Group #25by25: delivering €5 bn+ organic additional sales by 2025 >€1 bn organic sales growth per annum ~80% of each year from 2021 to 2025 >€1 bn growth from ~€25 bn1 BIG3 and > 6% organic CAGR >€1 bn Process illustration Solutions >€1 bn Healthcare New Products* >€1 bn Semiconductor Solution

  12. Slide 12: Portfolio strategy – from transformation to evolution

    Merck Group Portfolio strategy – from transformation to evolution Deleveraging and organic growth investments in focus until 2022 ▪ Primarily organic growth from ”BIG3“ Higher likelihood of ▪ Selective bolt-ons possible if budget allows regular bolt-ons Reduced probability of larger acquisitions pos

  13. Slide 13: Committing to record investments in BIG3 growth engines

    Merck Group Committing to record investments - targeted @BIG3 growth engines Leading positions in growth markets fuel Targeted, disciplined & focused capital allocation significant boost in investment capacity across >20 enterprise planning units Investment [in € bn] Life Science Healthcare Electron

  14. Slide 14: Optimized capital allocation through distinct portfolio roles

    Merck Group Optimized capital allocation through distinct portfolio roles Roles determined by thorough analysis of Investment focus on businesses with greatest markets and competitive positions strengths and attractive opportunities Competitive position illustration ▪ Segmentation in planning units

  15. Slide 15: Portfolio roles provide clear guidance to resource allocation

    Merck Group Portfolio roles provide clear guidance to resource allocation Simplified portfolio unit life cycle Invest for Manage Evaluate Growth Leadership for Cash ▪ Build/partner ▪ Back on track 1 ▪ Consider divestment Top-line growth Margin focus Transforma- tional M&A Bolt-on ( ) Invest (Capex/R

  16. Slide 16: Financial flexibility fueling investment capacity

    Merck Group Financial flexibility fueling investment capacity Accelerated deleveraging to <2x net debt Abundant growth opportunities make strategic capital to EBITDA pre ratio enables allocation more important than ever unprecedented financial flexibility Investment € bn share ▪ Strong operating cas

  17. Slide 17: Life Science: Focusing on profitable growth

    Life science Focusing on profitable growth

  18. Slide 18: Attractive secular drivers across segments create opportunities

    Life Science Market Attractive secular drivers across segments create opportunities Life Science market 1 2021: ~€190 bn ex COVID, growing 5 to 7% Portfolio Customer Geography Pharma largest (high single-digit) China fastest (double-digit) • Rising mAbs volume (11%) • Local mAb approvals Process 9 t

  19. Slide 19: Driving growth and expanding leadership in Process Solutions

    Life Science Driving growth and expanding leadership in Process Solutions Robust market with diverse growth Life Science will be fully equipped to capture growth pockets, elevated during pandemic opportunities with a focus on Process Solutions ▪ Major capacity and network expansion to fuel growth of

  20. Slide 20: Strong growth and improved mid-term outlook

    Life Science Strong growth and improved mid-term outlook Life Science mid-term sales outlook Drivers of strong mid-term outlook [in € m] ▪ LS-wide: Above-market performance with continued positive YoY growth rates despite expected fading 7 to 10% CAGR COVID-19 demand1 Research ▪ Process: Driving ~80

  21. Slide 21: All business units contributing to strong mid-term outlook

    Life Science All business units contributing to strong mid-term outlook 1 2 3 Sales split Mid-term outlook Customer Split Fundamental growth drivers ▪ Biologics: rising mAbs volume (11% CAGR4), growing adoption of single Process Solutions use, and shift to next-gen bioprocessing (intensified, digiti

  22. Slide 22: Focus on strengthening the core and expanding in high-growth areas

    Life Science Strategy Focus on strengthening the core and expanding in high-growth areas Productivity New Business Gains Models Expand in high growth Network & segments Holistic Capacity Expansion Offering Strengthen the core Go-To-Market Emerging Optimization Regions eCommerce ● Digital Solutions ●

  23. Slide 23: Process Solutions – the largest of the BIG3

    Process Solutions – the largest of the BIG3 Fueling the growth engine to accelerate further in a dynamic market Strategic Growth pillar Selected initiatives focus Products NA EU APAC ▪ Proactive capacity expansions for traditional Single Use Danvers Molsheim Wuxi ▪ Regionalization modalities ▪ Drivi

  24. Slide 24: Leveraging strong positions for durable growth in robust markets

    Leveraging strong positions for durable growth in robust markets Selected initiatives Research Solutions Strategic focus Selected initiatives Applied Solutions ✓ Building on strengths in research ✓ Lab Water instrument platform chemistry innovation ✓ Expanding Pharma QC testing ✓ Capitalizing on evo

  25. Slide 25: Innovation, digital and portfolio: key supporting pillars

    Innovation, digital and portfolio Key supporting pillars of strategy for value creation Innovation Digital Resource allocation Addressing evolving market … Internal Focus on organic growth… Sensing unmet customer Data & AI driven decisions Capex increasing ~2.5x1 needs and trends Building on tech st

  26. Slide 26: Healthcare: Executing on the earnings phase

    Healthcare Executing on the earnings phase

  27. Slide 27: Well positioned in a dynamic environment, focused leadership in R&D

    Healthcare Well positioned in a dynamic environment, focused leadership in R&D Existing market trends unchanged... Focused leadership in R&D driven by recent launches & pipeline ▪ High growth in largest TA Oncology ✓ From correlated to distinct ▪ Precision medicines to further increase share SCCHN u

  28. Slide 28: Growth driven primarily by innovation

    Healthcare Growth driven primarily by innovation, augmenting a solid established portfolio foundation Mid single-digit Positioned to accelerate CAGR science & technology leadership contribute to Profitable sales growth above global ~75% of growth pharmaceutical market (4.6% across TAs until 2025)1 N

  29. Slide 29: Healthcare: Base Business

    Healthcare: Base Business Ambition to keep base business ~stable throughout 2021 and 2022 Healthcare base business net sales until 2022 Rebif® ▪ Maintain solid track record of patient retention Decline in line with ▪ Integrate into joint franchise with Mavenclad® interferon market ▪ Drive EM1 growth

  30. Slide 30: Strengthening our leadership in Fertility

    Healthcare Strengthening our leadership in Fertility Global Gonadotropin market in € bn 1 Strategies to expand our leadership position GONAL-f The world’s most prescribed r-hFSH treatment3 +6,4% 2,4 ▪ Growing prevalence of infertility driven by delayed 2,3 2,2 parenthood and lifestyle habits 2,0 ▪ I

  31. Slide 31: Neurology & Immunology: Mavenclad hits record quarter

    Neurology & Immunology: Mavenclad® hits record quarter with sales up 33% (org.) YoY and equal growth contribution by U.S. and ex U.S. ▪ Recovery of US dynamic Sales development N&I, [€m] Dynamic market volume [R3W] 1 market dampened by COVID 19 delta wave org. org. org. org. org. [€m] 8.9% 4.5% -4.3

  32. Slide 32: Bavencio UC 1L launch

    Bavencio® UC 1L launch: Growing adoption of 1L maintenance therapy treatment and establishing stable market shares across key geographies U.S. - Approved in June 2020: YTD YTD YTD YTD YTD Newly diagnosed PT-based Maintenance 1L Maintenance Platinum metastatic 85% 70-75% chemo1 1L ~70% therapy 45-50%

  33. Slide 33: Healthcare catalysts

    Healthcare catalysts Oncology Immuno-Oncology Immunology Q4 2021 Q1 2022 Q2 2022 Tepotinib (c-Met–inhibitor) EMA: Filing accepted in Q4 2020, review ongoing Bavencio® Bintrafusp alfa (Avelumab/Anti-PD-L1) (TGFbeta trap/anti-PD-L1) 1L NSCLC (JAVELIN 100): 2L Cervical (INTR@PID 017): Expected data rea

  34. Slide 34: Electronics: Shifting gears to growth

    Electronics Shifting gears to growth execution

  35. Slide 35: Electronics industry has clear roadmaps with vast market potential

    Electronics industry has clear roadmaps with vast market potential and substantial need for materials innovation More applications than ever before to fuel Growth expected to accelerate… Semiconductor growth …with reduced upward cyclicality 12% Automotive 7% Server / Storage / Communication infrastr

  36. Slide 36: Building on leading positions in semiconductor materials

    Electronics Building on leading positions in semiconductor materials External trends drive strong demand Electronics well positioned to capture it Connected World IoT Big Data One of the strongest portfolios – providing solutions necessary to enable industry growth 5G Enabling breakthrough technolog

  37. Slide 37: Shifting gears from transformation to growth execution

    Electronics Shifting gears from transformation to growth execution From building a platform… …to executing on growth Successful “Bright Future” transformation 3 to 6% CAGR ▪ Superior business composition ~80% of 1 ▪ ~10 equally sized, differentiated tech platforms growth ▪ Wider customer base than e

  38. Slide 38: Portfolio refocus drives mid-term guidance upgrade to 3 to 6% CAGR

    Electronics Portfolio refocus drives mid-term guidance upgrade to 3 to 6% CAGR 1 2 3 Sales split Mid-term outlook Business Split Fundamental growth drivers ▪ Continued market growth due to technological advances (Artificial Semiconductor Solutions intelligence, 5G, Big Data and cloud, Internet of Th

  39. Slide 39: Electronics: Successful transformation, ready for accelerated growth

    Electronics: Successful transformation, ready for accelerated growth An integrated electronics innovation leader Delivering on promises and above with one of strongest industry portfolios Bright Future program key deliverables & savings Surface Conducting Solutions thin films €3.3 bn sales with Acti

  40. Slide 40: Level Up - Shifting gears from transformation to growth execution

    “Level Up” - Shifting gears from transformation to growth execution Level up scale Enabling ambition Level up tech ▪ Capacity investments of 3 to 6% org. CAGR ▪ Further sharpen focus on synchronized to customers’ 2021 to 2025+ profitable innovation, addressing expansion plans key inflection points ▪

  41. Slide 41: Sustainability

    Sustainability

  42. Slide 42: Our sustainability goals

    Boundaries of human progress today will become reality tomorrow: Our sustainability goals Positive impact through our products Dedicated to human progress ▪ Give access to medicine In 2030, we will advance human progress for ▪ Enable cutting edge technologies 01 >1 bn people through sustainable scie

  43. Slide 43: Expanding KPIs to monitor and steer sustainability

    Merck Group Expanding KPIs to monitor and steer sustainability comprehensively Goal Exemplary KPIs to be implemented in 2021 Our sustainability ambition is integrated in the Executive 01 # of people positively impacted by Merck technologies/products Board remuneration system Human Progress % of new

  44. Slide 44: Reducing our ecological footprint

    Reduce our environmental footprint: 03 Reducing our Goal ecological footprint Emissions, Water and Waste Enhance water Climate neutrality efficiency, reduce Reduce waste impact by 2040 harmful emissions ▪ Aiming for climate neutrality ▪ Enhancing water efficiency and ▪ Based on the Merck Waste (scop

  45. Slide 45: Diverse human capital

    Merck Group Diverse human capital: Thinking, talking, and leading differently Focus areas Status quo 2020 Aspirations Gender parity* Gender 35% women in leadership globally until 2030 20% of underrepresented ethnic colleagues in US Increase to 30% leadership until 2030 Culture & Ethnicity 16% of nat

  46. Slide 46: Clear set of tasks to enable our 2030 ESG goals

    Merck Group Clear set of tasks to enable our 2030 ESG goals Tasks Development In place Results and next steps Analysis of requirements: Strategy, Ongoing due to developing field of ESG business, regulation, stakeholders stakeholder expectations and regulation Build effective data platform for Feed i

  47. Slide 47: On the path towards climate neutrality 2040

    Outlook: On the path towards climate neutrality 2040 Climate Nov. 2021 Dec. 2021 Q2 2022 2030 2040 Neutrality Submit validation Work on SBT Develop towards Certification by SBTi documents for roadmap towards climate neutrality expected1 SBTi certification climate targets (2040) ▪ Aiming for climate

  48. Slide 48: Guidance and Executive summary

    Guidance and Executive summary

  49. Slide 49: Full-year 2021 guidance

    Full-year 2021 guidance Net sales: Organic: +13% to +15% YoY FX: -1% to -2% YoY ~€19.30 bn to €19.85 bn EBITDA pre: Organic: +26% to +29% YoY (excl Biogen1) FX: -1% to -2% YoY ~€6.00 bn to €6.30 bn EPS pre: ~ €8.50 to €9.00 1 Q3 20 reversal of the provision for the patent dispute over Rebif in the a

  50. Slide 50: Executive Summary

    Executive Summary 4 key priorities to deliver on Our science & tech ambitions Focusing on Sustainability Mobilizing for Driving Efficient growth Culture & Leadership Leveraging Innovation in the BIG3 50 From: Merck Capital Markets Day 2021 – 2021.09.09

  51. Slide 51: Appendix

    Appendix RPAQGRTK

  52. Slide 52: Group

    Group

  53. Slide 53: 2021 business sector guidance

    1 2021 business sector guidance Net sales EBITDA pre Life Science ▪ Organic: +20% to +22% ▪ Organic:+36% to +39% YoY ▪ Process Solutions as main ▪ FX: -1% to -2% YoY growth driver, including ▪ ~€3,200 – 3,350 m ~€1 bn COVID-19 sales EBITDA pre Net sales Healthcare ▪ Organic: +8% to +9% ▪ Organic:+17

  54. Slide 54: Additional financial guidance 2021

    Additional financial guidance 2021 Further financial details Corporate & Other EBITDA pre ~ €-440 to -470 m Interest result ~ €-190 to -220 m Effective tax rate ~22% to 24% Capex on PPE ~€1.4 bn FY 2021 hedge ratio ~70% Hedging/USD assumption at EUR/USD ~1.17 2021 Ø EUR/USD assumption ~1.17 to 1.19

  55. Slide 55: Effective tax rate guidance lowered to 22% to 24%

    Effective tax rate guidance lowered to new range of 22% to 24% Tax rate development 2018-2020 and from 2021 onwards Rationale for update 40.0% Strong profit growth in Old guidance range ~24 - 26% New guidance range ~22 - 24% Life Science results in different profit 30.0% Q1 2021 contributions worldw

  56. Slide 56: Focus on organic growth and further deleveraging

    Merck Group Focus on organic growth and further deleveraging Proven swift deleveraging Net debt / EBITDA pre track record & outlook after major acquisitions 4.0 ▪ Deleveraged to ~2x net 3.5 debt/EBITDA pre already in 2020 2.8 ▪ M&A on hold until 2022; only smaller deals to be realized if 2.1 budget

  57. Slide 57: Sustainable dividend growth

    Sustainable dividend growth Dividend development 2014 - 2020 2020 dividend ▪ Dividend of €1.40 (+8% YoY) per share approved1 by Annual General Meeting 1.40 2 1.25 1.25 1.30 ▪ Payout ratio of 23.1% of EPS pre in 1.20 2020; aiming for 20-25% of EPS pre 1.00 1.05 3 ▪ Dividend yield of 1.0% 1April 28, 2

  58. Slide 58: Merck's ownership structure

    Merck Group Merck‘s ownership structure Shareholders E. Merck KG: of Merck KGaA Partners‘ Meeting & Family Board ▪ Shareholders hold ~30% of Merck KGaA’s total capital ▪ E. Merck KG (99.9% Merck Family) holds ~70% of Merck ▪ Share capital is divided into 129,242,252 bearer shares KGaA’s total capita

  59. Slide 59: Executive board compensation

    Merck Group: Executive board compensation Pay for performance reflecting the company’s long-term strategy Long-Term Incentive Merck Long-Term Plan Plan Incentive ▪ Reflecting the long-term strategy for Merck’s growth and (from 2022) sustainability ambition Performance of Merck 50% share price vs. th

  60. Slide 60: Strategic focus areas in sustainability

    Merck Group Strategic focus areas in sustainability Sustainability innovation and technology Sustainability culture & values for our customers  Diversity & inclusion activities  Sustainability as integral part of product design  Sustainability mindset: Communication, trainings,  Enable customers

  61. Slide 61: External stakeholders assess our engagement

    Merck Group External stakeholders assess our engagement As of 2021, Merck received In September 2021, we Since 2008, Merck is part In 2020, Merck has once an MSCI ESG* Rating improved our ESG Risk of FTSE4Good Index, more achieved prime status of AAA. Rating to 18,3 and were measuring the performanc

  62. Slide 62: Regular portfolio review remains key to success

    Merck Group Regular portfolio review remains key to success Strong Defining portfolio Clear financial track record guard rails M&A criteria ▪ Acquisitions and divestments are ▪ Three strong pillars with no ▪ Supporting profitable growth part of Merck’s history business marginalized strategy ▪ Licens

  63. Slide 63: Life Science demand primary driver of growth across all regions

    Continued strong Life Science demand primary driver of growth across all regions Regional breakdown of net sales [€m] Regional organic development Europe +15.6% ▪ APAC: Life Science and Electronics org. largest contributors to growth 29% particularly in Process Solutions, and Semiconductor Solutions

  64. Slide 64: 11% organic sales growth driven by all three business sectors

    11% organic sales growth driven by all three business sectors; EBITDA pre growing 13% organically (excluding Biogen) Q3 YoY Net Sales Q3 YoY EBITDA pre Organic Currency Portfolio Total €1,701 m Life Science 17.1% 0.6% 0.0% 17.7% 2.2% €1,552 m -10.9% -0.1% Healthcare 4.1% 1.0% -0.1% 5.1% Electronics

  65. Slide 65: Strong 9M performance across all three business sectors

    Strong 9M performance across all three business sectors; Life Science growing 24% organically in the first 9 months of 2021 9M YoY Net Sales 9M YoY EBITDA pre Organic Currency Portfolio Total 20.3% €4,639 m Life Science 23.9% -3.5% 0.0% 20.4% €3,956 m -2.9% -0.1% Healthcare 9.9% -3.0% -0.5% 6.4% Ele

  66. Slide 66: Credit details

    Credit details Maturity profile as of Sep 30, 2021 Credit rating information Coupon [€m / $m] 3.250% 0.125% LT ST Since Outlook Rating Rating 2.950% 1.375% Baa1 1 12.12.14 Stable P-2 1,600 1.625% 3.375% 1.625% 2.875% 1,000 0.875% 0.500% A 29.05.13 Stable A-1 0.005% 500 0.375% 1.000 1.000 750 750 800

  67. Slide 67: Q3 2021: Overview

    Q3 2021: Overview Key figures (Excl. Biogen provision reversal) Comments [€m] Q3 2020 Q3 2021 Δ Q3 2020 Δ ▪ Growth across all sectors, particularly Net sales 4,447 4,973 11.8% Life Science, further supported by +1% FX tailwind results in +12% sales growth EBITDA pre 1,701 1,552 -8.7% 1,336 16.2% 38.

  68. Slide 68: 9M 2021: Overview

    9M 2021: Overview Key figures (Excl. Biogen provision reversal) Comments [€m] 9M 2020 9M 2021 Δ 9M 2020 Δ ▪ Strong YTD performance across all three Net sales 12,936 14,474 11.9% Sectors. Particularly Life Science drives 12% growth in the first 9 months EBITDA pre 3,956 4,639 17.3% 3,591 29.2% Margin

  69. Slide 69: Q3 2021: Reported figures

    Q3 2021: Reported figures – comps impacted by Biogen provision Reported results Comments [€m] Q3 2020 Q3 2021 Δ EBIT 1,167 1,047 -10.2% ▪ Underlying EBIT growing 31% while reported EBIT growth impacted by Financial result -102 -54 -46.7% Q3 2020 €365 m provision reversal Profit before tax 1,065 993

  70. Slide 70: 9M 2021: Reported figures

    9M 2021: Reported figures – impacted by Q3 2020 Biogen provision Reported results Comments [€m] 9M 2020 9M 2021 Δ ▪ EBIT growing 32%, despite Biogen, 2,374 3,140 32.3% driven primarily by operating leverage EBIT in Life Science, Bavencio® and soft Financial result -302 -208 -31.2% comps in Fertility

  71. Slide 71: Cash flow statement Q3 2021

    Cash flow statement Q3 2021 – Cash flow statement Cash flow drivers [€m] Q3 2020 Q3 2021 Δ ▪ Operating cash flow up €296 m driven Profit after tax 806 764 -43 primarily by higher underlying profit D&A after tax, particularly in Life Science 451 443 -8 ▪ Negative delta in profit after tax impacted Ch

  72. Slide 72: Cash flow statement 9M 2021

    Cash flow statement 9M 2021 – cash flow statement Cash flow drivers [€m] 9M 2020 9M 2021 Δ Profit after tax 1,554 2,258 705 ▪ Operating cash flow growing €1.4 bn or +63% vs. 9M 2020 D&A 1,442 1,287 -156 ▪ Profit after tax primary driver, with Changes in provisions -294 246 540 +€705 m (muted by 2020

  73. Slide 73: Adjustments in Q3 2021

    Adjustments in Q3 2021 Adjustments in EBIT [€m] Q3 2020 Q3 2021 Adjustments thereof D&A Adjustments thereof D&A Healthcare 4 0 9 0 Life Science 18 0 18 0 Electronics 28 1 38 18 Corporate & Other 31 0 11 1 Total 82 1 76 19 73 Merck Q3 2021 Results Presentation | November 11, 2021

  74. Slide 74: Adjustments in 9M 2021

    Adjustments in 9M 2021 Adjustments in EBIT [€m] 9M 2020 9M 2021 Adjustments thereof D&A Adjustments thereof D&A Healthcare -8 2 30 3 Life Science 15 0 26 0 Electronics 194 112 65 25 Corporate & Other 56 0 114 1 Total 256 114 235 30 74 Merck Q3 2021 Results Presentation | November 11, 2021

  75. Slide 75: Financial Calendar

    Financial Calendar Date Event March 3, 2022 Q4 2021 Earnings release April 22, 2022 Annual General Meeting May 12, 2022 Q1 2022 Earnings release August 4, 2022 Q2 2022 Earnings release November 10, 2022 Q3 2022 Earnings release 75 Merck Q3 2021 Results Presentation | November 11, 2021

  76. Slide 76: Life Science

    7 Life science

  77. Slide 77: Therapies are evolving from treatments to cures

    Process Solutions: Therapies are evolving from treatments to cures Advancing traditional is critical as novel modalities develop TRADITIONAL MODALITIES NOVEL MODALITIES Uses small molecules, Uses DNA, RNA, Cells peptides, proteins HP-API Gene & Viral Chronic, Plasma ADCs Potentially curative manages

  78. Slide 78: Moving from today's technology to BioPharma 4.0

    Process Solutions Moving from today’s technology to BioPharma 4.0 Unit Operations Intensified, integrated, digitally-enabled Cell culture media mAbs templated Next generation 30 years ago bioprocessing Biopharm materials Intensified Processing Chromatography > > > Value for customers Perfusion Natri

  79. Slide 79: COVID demands align with existing strengths

    Process Solutions COVID demands align with existing strengths COVID-19 Outlook Product offering Type & Global Doses Implications Capabilities in all unit operations Nucleic Acid Vaccines • Leveraging human 4.8 Billion Gov. contracted factory 4.3 Billion 2021 manuf. • Emerging manuf. process CCM & Pl

  80. Slide 80: Process Solutions: Strategic direction

    Process Solutions: Strategic direction Innovate and invest today to continue above market growth in the future Modality TRADITIONAL ALL NOVEL Revenue Near term Mid term Long term driver Offering Products Services Products Portfolio Single Use Manufacturing novel therapies Perfusion Bioreactor Gene t

  81. Slide 81: Opportunities in services to accelerate double-digit growth

    Process Solutions Opportunities in services to accelerate double-digit growth Accessible Market (€ bn) mAbs dominate; Novels fastest Importance of services and novel modalities increases +13% 5 2021 10 19 2 31 7 50 3 31 4 2025 17 28 5 50 2021 Small Other mAbs & Cell & gene 2025 1 2 Molecules biologi

  82. Slide 82: Next-generation bioprocessing on the cards

    Process Solutions Next-generation bioprocessing on the cards process & portfolio Launched 2018 Launched 2018 Today’s CHOZN Ex-Cell® Mobius® Clarisolve® Eshmuno® Viresolve® ProSep® Opticap® Pellicon® Durapore® Millipak® Cell Line Advanced™ bioreactor Depth Filters Chrom. resin Pro Solution Ultra Plus

  83. Slide 83: Single-use technologies drive flexibility

    Process Solutions Our single-use technologies drive flexibility in modern bioprocessing 30,000 l 500 l stain-less single-use steel tank tank Traditional multi-use facility Innovative Single-use facility CAPEX* required ~$500 m to $1 bn CAPEX required $20 m to $100 m Time to construct 5 to 10 years T

  84. Slide 84: mAbs market democratization will drive diversification

    Process Solutions mAbs market democratization will drive diversification, change & variability mAb volume projections 2021 to 2025 45 CAGR ~11% Market 40 Biosimilars1 development 35 • mAbs market will grow ~11% CAGR • Top 10 originator mAbs represent Volume [metric tons] 30 ~45% (11mT) of volume tod

  85. Slide 85: Process Solutions: record Q3 2021

    BIG 3 - Process Solutions: record Q3 2021 in absolute terms, declining growth rate against tough comps Sales development [€m] - org. growth [%] 1,186 1,145 ▪ Continued strong growth in the core 1,054 business paired with still increasing COVID- 975 19 contributions (mainly vaccine related) 892 926 3

  86. Slide 86: Research Solutions: Normalizing org. growth

    Research Solutions: Normalizing org. growth against tougher comps Sales development [€m] - org. growth [%] 644 631 602 30.9% 608 ▪ Organic growth now moderating to 7% as 566 546 Q3 2020 comparables include strong post Q2 24.0% lockdown catch-up and recovery as well as 501 additional COVID-19 demand

  87. Slide 87: Applied Solutions: record absolute sales

    Applied Solutions: record absolute sales, normalizing growth rate Sales development [€m] - org. growth [%] 453 449 454 421 432 413 418 ▪ Growth remains on elevated level due to ongoing post-lockdown recovery ▪ Core business remains main driver with 12.8% broad-based performance across business lines

  88. Slide 88: Life Science Q3: Strong core business and COVID-19 demand

    Life Science Q3: Strong core business and COVID-19 demand drive another quarter of record sales Life Science P&L Net sales bridge [€m] IFRS Pre 17.1% 0.6% 0.0% €2,248 m €1,910 m Q3 2020 Q3 2021 Q3 2020 Q3 2021 Net sales 1,910 2,248 1,910 2,248 M&S * -478 -529 -477 -527 +0.0% Admin -88 -93 -80 -84 Q3

  89. Slide 89: Healthcare

    7 Healthcare

  90. Slide 90: Healthcare pipeline November 11, 2021

    Healthcare pipeline November 11, 2021 Phase I Phase II Phase III M1231 M6223 berzosertib bintrafusp alfa xevinapant Bispecific MUC1xEGFR anti-TIGIT mAb ATR inhibitor TGFbeta trap/anti-PD-L1 IAP inhibitor ADC Solid tumors3 Small-Cell Lung Cancer4 Cervical cancer 2L Locally advanced squamous cell carc

  91. Slide 91: China's VBP: Round 4 implemented

    China‘s VBP: Round 4 implemented, confidence in approx. stable base business through 2021 and 2022 sustained Round 1 Round 2 Round 3 Round 4 2019 2020 2021 March: First December: April: Round 2 July: Round 3 Jan: Round 4 announced (incl. round Round 2 winners granted announced calcium dobesilate3 an

  92. Slide 92: Xevinapant: potential to become standard of care

    Xevinapant Potential to become standard of care in core area for Merck Chart originally presented in 2020 R&D update call; selected, non-exhaustive examples Worldwide Selected DDR assets M9831 xevinapant in-licensing External (incl. M6620/Berzosertib) (formerly Xevinapant VX984)3 builds on leadershi

  93. Slide 93: Xevinapant (Debio 1143)

    Xevinapant (Debio 1143) Potentially first in class oral IAP antagonist with FDA BTD Compelling Phase 2 data2 published in The Lancet Oncology, Mode of Action1 and presented at ESMO 2020 ▪ Improvement in OS statistically significant and clinically meaningful: HR 0.49 (0.26–0.92); p=0.0261 ▪ Clinicall

  94. Slide 94: Xevinapant deal volume and royalties

    Xevinapant Total deal-volume of up to ~ €900 m and industry-typical sales royalties Payment type Amount (in €) Accounting treatment2 Upfront payment ~ €190 m Largest part to be capitalized as an intangible asset Approval To be paid and capitalized as an intangible asset upon approval and to be Up to

  95. Slide 95: Two Phase III studies are designed

    Xevinapant (Potentially first in class oral IAP antagonist) Two Phase III studies are designed to target the majority of unresectable LA SCCHN patients receiving systemic therapy + RT 2020 2021 2022 … 2025 … 1 Registrational ▪ Cisplatin-eligible LA SCCHN Phase III Initiated in September 2020; ▪ Xevi

  96. Slide 96: Mavenclad: independent real-world data

    Healthcare: Mavenclad® Independent real-world data (RWD) differentiates Mavenclad® ▪ A high-efficacy DMT that demonstrates full antibody response to COVID-19 vaccination ▪ Differentiated vs. other high-efficacy therapies in light of COVID-19 vaccinations for MS patients Total Protective humoral Pati

  97. Slide 97: Tepotinib: First-in-class launch in MET Exon14

    Tepotinib (MET kinase inhibitor) First-in-class launch in MET Exon14 sets foundation for EGFRm/ METamp opportunity and exploration in other tumor types • Highly competitive data set presented at ASCO 2020 and published in New England Lay the Foundation in Journal of Medicine in May 2020 (99 patients

  98. Slide 98: Tepotinib: EGFRmut/METamp market, INSIGHT 1 data

    Tepotinib (MET kinase inhibitor) Tapping into the rapidly evolving EGFRmut/METamp market – Encouraging INSIGHT 1 data INSIGHT 2 – Tepotinib + Osimertinib in A solid foundation - Encouraging INSIGHT 1 data Osimertinib Relapsed METamp NSCLC (18-months follow-up presented at WCLC 2019)2 • Study design

  99. Slide 99: Bavencio UC 1L maintenance treatment

    Bavencio® (Avelumab) – Urothelial Carcinoma (UC 1L) UC 1L maintenance treatment achieving transformative OS benefit (31% reduction in risk of death, 7 months increase in median overall survival) Durable responses to standard of care (1L chemotherapy) are rare with most patients experiencing progress

  100. Slide 100: Leading DDR portfolio with a broad clinical program

    DNA Damage Response (DDR) 4 Leading DDR portfolio with a broad clinical program ▪ Only ATR-inhibitor with a POC from an RCT Strategy presented at R&D (Ovarian cancer, Berzosertib +/- Gem) Update Call 2019 ▪ Promising Ph II POC data from NCI study recently Berzosertib/M6620 published in Cancer Cell (

  101. Slide 101: Evobrutinib: BTKi development for MS

    We pioneered BTKi development for MS with Evobrutinib Potential to have 3 complementary MS branded products by 2025 Unmet need in Multiple B-Cell Targeting + Worldwide MS Sclerosis (MS) – High-Efficacy (HE) Orals Need for new mechanisms to Market [€ bn]1 represent >60% of MS sales control disease 20

  102. Slide 102: Evobrutinib stands out amongst BTK inhibitors

    Evobrutinib stands out amongst BTK inhibitors under development Uniquely positioned both in terms of clinical evidence and mode of action Fenebrutinib## Tolebrutinib** Evobrutinib Long-term* efficacy on relapses (1) Clinical Evidence (1) Long-term* safety Convenience BID BID QD (oral) Exposure in (2

  103. Slide 103: Evobrutinib targets inflammation and progression

    Evobrutinib targets inflammation and progression Dual mechanism of action offers an innovative oral approach to MS therapy MOA on B-cells and Evobrutinib shifts Evobrutinib reduces macrophage/microglia cells is Evobrutinib is a CNS macrophage phenotypes CNS B cells and an innovative oral penetrant B

  104. Slide 104: Evobrutinib is optimally dosed for BTK inhibition

    Evobrutinib is optimally dosed to offer best-in-class BTK inhibition Optimized dose selection & targeted covalent binding results in sustained BTK inhibition that is necessary for robust efficacy Sustained BTK inhibition in CNS-resident and CNS-migrating cells resulting from covalent binding MOA and

  105. Slide 105: Evobrutinib long-term data in MS

    Evobrutinib Evobrutinib holds unmatched Long-Term Data among BTKi class in MS (BTK-inhibitor) Best-in-disease efficacy & favorable safety over 2 years in largest Phase II study in MS Very high, Early and substantial impact ▪ Evobrutinib is the only BTKi to have demonstrated very high, sustained sust

  106. Slide 106: M5049: TLR7/8 drivers of SLE and COVID-19

    M5049 (TLR7/8 antagonist) TLR7/8 are drivers of SLE pathology and possibly of COVID-19 2 • M5049 (discovered in-house) is a potentially first-in class small molecule that blocks activation of Toll-like receptors TLR7 and TLR8, two innate immune sensors that detect single-stranded (ss) RNA from virus

  107. Slide 107: M5049: Similarities between SLE and COVID-19

    M5049 (TLR7/8 antagonist) Similarities between SLE and COVID-19 Similarities between SLE and COVID-191 Phase II study started in July 2020 Rational: • Investigate if M5049 intervention at critical point in course of COVID-19 disease may prevent or ameliorate hyper- inflammatory response in patients

  108. Slide 108: Healthcare Q3: Bavencio and Mavenclad drive growth

    ® Healthcare Q3: Strong Bavencio performance and continued ® Mavenclad ramp-up drive 4% organic growth Healthcare P&L Net sales bridge [€m] IFRS Pre €1,702 m 4.1% 1.0% €1,788 m -0.1% Q3 2020 Q3 2021 Q3 2020 Q3 2021 Net sales 1,702 1,788 1,702 1,788 * M&S -382 -386 -379 -386 Admin -75 -79 -75 -77 Q3

  109. Slide 109: Electronics

    7 electronics

  110. Slide 110: Targets attractive markets in electronics

    Electronics Targets attractive markets – especially in the electronics space Automotive Electronics Market • Driven by world GDP Electronics growth Market sales by end market • Increasing demand in emerging markets Market size: ~€2,000 bn Market size1: 2020A ~€1,800 bn ~89% ~11% CAGR 20-25: Sales ~5

  111. Slide 111: Semiconductor Solutions – integrated materials player

    Semiconductor Solutions – integrated materials player, well positioned to serve the need of customers in semiconductor fabrication Electronics 1 [in € bn] Semiconductors 2 [in € bn] Semiconductor Solutions 1,800 368 Semiconductor 47 Semiconductor Silicon wafers 370 Materials components 54 Patterning

  112. Slide 112: Comprehensive products and services portfolio

    Unique comprehensive products and services portfolio offers end-to-end solutions, well-placed in high growth segments Deposition Steps of Merck customers in manufacturing integrated circuits Patterning Planarization Wafer processing offers highest value creation potential in Prototyping value chain

  113. Slide 113: Over 100 customers

    Beyond a comprehensive portfolio Semiconductor Solutions also has an industry spanning customer base, supplying various end markets 1 2 2019 wafer capacity by region Selected customers per region Taiwan 19% Semiconductor Solutions has over 100 S. Korea 19% Customers Japan 18% supplying all top 10 ch

  114. Slide 114: Only 3 companies run volume production ≤10nm

    Only 3 companies are currently running volume production ≤10nm These companies have the largest market shares across all nodes 1 Number of companies currently running volume production per logic chip node 20 19 14 10 6 4 4 3 2 130nm 90nm 65nm 45/40nm 32/28nm 22/20nm 16/14nm 10/7nm 5/3nm CN EU JP KR

  115. Slide 115: Technology trends drive exponential data growth

    Technology trends inevitably drive exponential data growth… …more chips needed to generate, transfer, process & store data Data created worldwide All segments of data application Technology trends strongly impact is growing +30% annually are affected by global data growth relevance of data applicati

  116. Slide 116: Level Up Scale - Expanding in synch with customer demand

    “Level Up” Scale - Expanding in synch with customer demand A partner of choice, in step for higher demand Smart localization, investing close to customers Semiconductor industry CAPEX p.a.1 [bn€] Share of semi > 2X material market1 Key investments ? Investing in lock-step with Taiwan ▪ Additional la

  117. Slide 117: Level Up Tech - delivering today and enabling tomorrow

    “Level Up” Tech – delivering today and enabling tomorrow Strong portfolio of silicon & optical technologies And enabling tomorrow’s empowering today’s applications leading-edge technologies Solutions empowering customers to make Selected future Our smaller, faster, more energy efficient & more susta

  118. Slide 118: Expanding the limits of how small you can go

    Electronics Expanding the limits of how small you can go Pattern collapse AZ® rinse materials As lines get narrower and closer together in advanced chip generation, lines tend to “stick” due to surface tension. Lithography limitation Directed self-assembly (DSA) Block copolymer can generate small li

  119. Slide 119: OLED material market to exceed LC material market

    Electronics Display Solutions - OLED material market to exceed LC material market already in 2021 x% OLED shipment area / addressable material market [in % of total] Liquid Crystals OLED Display shipment area1 Addressable material market2 [km²] [€m] +20% -8% +4% +7% 264 246 1,694 1,450 1,109 1,139 1

  120. Slide 120: Strategic roadmap materializing

    Electronics Strategic roadmap materializing Measures for a bright future Darmstadt  In Darmstadt focus on R&D and  Leading supplier of high-purity process production chemicals, gases and equipment  Immediate bottom line contribution serving semiconductor manufacturers from 2019 onwards  Track re

  121. Slide 121: Successful integration drives substantial synergy upgrade

    Electronics Successful integration drives substantial synergy upgrade and acceleration EBITDA pre impact of synergy ramp-up [€ m] Sources of synergies ~50 ~83 ~95 10 Business • Transform country setup 8 10 Optimization • Streamline duplicate structures 35 30 75 • Optimize production and ~75 Procurem

  122. Slide 122: Electronics Q3: 21% growth in Semi

    Electronics Q3: 21% growth in Semi continue to drive double-digit organic sales growth Electronics P&L Net sales bridge 10.3% 1.7% 0.0% €937 m [€m] IFRS Pre €836 m Q3 2020 Q3 2021 Q3 2020 Q3 2021 Net sales 836 937 836 937 M&S * -133 -147 -132 -145 +0.0% Admin -38 -39 -36 -28 Q3 2020 Organic Currency

  123. Slide 123: Investor Relations contacts

    CONSTANTIN FEST SVENJA DJAVAHERI SARA HOFMANN Head of Investor Relations Assistant Investor Relations Assistant Investor Relations +49 6151 72-5271 +49 6151 72-3744 +49 6151 72-3321 [email protected] [email protected] [email protected] ILJA DOERING GUNNAR ROMER A

Merck KGaA, Darmstadt, Germany — Morgan Stanley European Technology, Media & Telecom Conference 2021 on 6ix